Dormancy in solid tumors: implications for prostate cancer.
Dormancy in solid tumors: implications for prostate cancer.
复制标题
DOI：
10.1007/s10555-013-9422-z
复制
发表时间：
2013-12
影响因子：
9.2
通讯作者：
Vessella, Robert L.
中科院分区：
文献类型：
--
作者：
Ruppender, Nazanin S.;Morrissey, Colm;Lange, Paul H.;Vessella, Robert L.
在癌症休眠中，残留的肿瘤细胞持续存在于没有明显临床症状的患者身上，只是在以后可能变得与临床相关。在前列腺癌(PCA)中，原发肿瘤通常被切除，许多患者在复发前经历了一段较长的时期(>；5年)，没有疾病的证据。这些特性使得PCA成为研究肿瘤细胞休眠的一个很好的候选者。然而，构成PCA休眠的机制还没有明确的定义。此外，文献中对肿瘤细胞休眠的定义各不相同。因此，在这篇综述中，我们将肿瘤细胞休眠分为三类：(A)微转移休眠-一组由于限制性的增殖/凋亡平衡而不能增加数量的肿瘤细胞。(B)血管生成休眠--一组肿瘤细胞，由于缺乏血管生成潜能而不能扩展到形成微转移之后。(C)条件性休眠--如果没有微环境的适当提示，单个细胞或极少数细胞不能增殖，但不需要血管生成来实现。本综述旨在确定目前已知的肿瘤休眠的标记物、机制和模型，特别是与PCA相关的标记、机制和模型，并强调当前在我们对临床癌症休眠的理解方面取得进展的机会。
In cancer dormancy, residual tumor cells persist in a patient with no apparent clinical symptoms, only to potentially become clinically relevant at a later date. In prostate cancer (PCa), the primary tumor is often removed and many patients experience a prolonged period (>5 years) with no evidence of disease before recurrence. These characteristics make PCa an excellent candidate for the study of tumor cell dormancy. However, the mechanisms that constitute PCa dormancy have not been clearly defined. Additionally, the definition of tumor cell dormancy varies in the literature. Therefore, we have separated tumor cell dormancy in this review into three categories: (A) Micrometastatic dormancy - A group of tumor cells that cannot increase in number due to a restrictive proliferation/apoptosis equilibrium. (B) Angiogenic dormancy- A Group of tumor cells that cannot expand beyond the formation of a micrometastasis due to a lack of angiogenic potential. (C) Conditional dormancy- An individual cell or a very small number of cells that cannot proliferate without the appropriate cues from the microenvironment, but do not require angiogenesis to do so. This review aims to identify currently known markers, mechanisms and models of tumor dormancy, in particular as they relate to PCa, and highlight current opportunities for advancement in our understanding of clinical cancer dormancy.
登录
查看更多内容
影响因子：
11.2
作者：
Attard, Gerhardt;Swermenhuis, Joost F.;de Bono, Johann S.
通讯作者：
de Bono, Johann S.
影响因子：
11.2
作者：
Barkan D;Kleinman H;Simmons JL;Asmussen H;Kamaraju AK;Hoenorhoff MJ;Liu ZY;Costes SV;Cho EH;Lockett S;Khanna C;Chambers AF;Green JE
通讯作者：
Green JE
DOI：
10.1073/pnas.92.20.9363
发表时间：
1995-09-26
影响因子：
11.1
作者：
DIMRI, GP;LEE, XH;CAMPISI, J
通讯作者：
CAMPISI, J
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF
影响因子：
11.5
作者：
Danila, Daniel C.;Heller, Glenn;Scher, Howard I.
通讯作者：
Scher, Howard I.